Markets:

Overview

News

Currencies

International

Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

7.825 +0.135 (+1.76%)

Streaming Delayed Price Updated: 10:07 AM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Vanda Pharmaceuticals Inc (VNDA) Q2 2021 Earnings Call Transcript ↗

July 29, 2021

VNDA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Vanda Pharmaceuticals: Q2 Earnings Insights ↗

July 28, 2021

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 6.25% year...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Earnings Scheduled For July 28, 2021 ↗

July 28, 2021

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.55 per share on revenue of $7.90 billion. • United...

Via Benzinga

BridgeBio Pharma Stock Sees Rising Relative Strength; Still Shy Of Key Threshold ↗

July 01, 2021

In a welcome move, biotech BridgeBio Pharma stock saw its Relative Strength Rating rise from 70 to 73 on Thursday.

Via Investor's Business Daily

Translate Bio Stock Flashes Improved Technical Strength Rating; Triple-Digit Sales Growth ↗

June 28, 2021

Translate Bio shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Earnings Scheduled For May 5, 2021 ↗

May 05, 2021

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

Crispr Therapeutics Stock Sees Improved Relative Strength Rating ↗

June 25, 2021

Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74.

Via Investor's Business Daily

Stocks That Hit 52-Week Highs On Thursday ↗

July 01, 2021

This morning 158 companies set new 52-week highs. Intriguing Points: NVIDIA (NASDAQ:NVDA) was the largest firm on a market cap basis to set a new 52-week high. The...

Via Benzinga

Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating ↗

June 17, 2021

Cel-Sci sees its Relative Strength Rating hit the 80-plus level.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021 ↗

May 12, 2021

Upgrades Craig-Hallum upgraded the previous rating for ShotSpotter Inc (NASDAQ:SSTI) from Hold to Buy. For the first quarter, ShotSpotter had an EPS of $0.02, compared to...

Via Benzinga

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗

May 11, 2021

On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching.

Via Investor's Business Daily

Vanda Pharmaceuticals Inc (VNDA) Q1 2021 Earnings Call Transcript ↗

May 05, 2021

VNDA earnings call for the period ending December 31, 2020.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.